Lead Product(s) : Resiquimod
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Bioluminescence Ventures
Deal Size : $32.0 million
Deal Type : Series B Financing
Details : The funding will be used for the further development of company's intraoperative immunotherapy, SURGERx with resiquimod (STM-416), in patients with recurrent bladder cancer.
Product Name : STM-416
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 19, 2023
Lead Product(s) : Resiquimod
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Bioluminescence Ventures
Deal Size : $32.0 million
Deal Type : Series B Financing
Lead Product(s) : Resiquimod
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STM-416 (Resiquimod), is a TLR7 and TLR8 agonist which is being invstigated for prevention of recurrence or progression after transurethral resection of bladder tumor (TURBT) in patients with non-muscle invasive bladder cancer (NMIBC)
Product Name : STM-416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2023
Lead Product(s) : Resiquimod
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Resiquimod
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TransCon TLR7/8 Agonist is an investigational long-acting prodrug of resiquimod, a small molecule agonist of Toll-like receptors (TLR) 7 and 8 designed to provide sustained activation of intratumoral antigen-presenting cells driving tumor antigen present...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 11, 2022
Lead Product(s) : Resiquimod
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Resiquimod
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14
Details : Resiquimod, a small molecule agonist of Toll-like receptors, is designed to provide sustained activation of intratumoral antigen presenting cells driving tumor antigen presentation and induction of immune stimulatory cytokines in the tumor.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2021
Lead Product(s) : Resiquimod
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable